---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-000844"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T19:00:23.499475+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ZyVersa appoints Sapirstein, Freitag, and Rupalla to board post-business combination

## Summary
- ZyVersa appoints James Sapirstein (FWBI CEO), Gregory Freitag (PDSB board), and Katrin Rupalla to its board effective Jan 5, 2023.
- Appointments fill three vacancies from the Dec 12, 2022 business combination with Larkspur Health Acquisition Corp.
- Sapirstein to serve on Compensation & Nominating Committees; receives $40k annual retainer plus $11.5k committee fees.
- Freitag to chair Audit and serve on Nominating Committee; receives $40k retainer plus $22.5k committee fees.
- Rupalla to chair Nominating Committee; receives $40k retainer plus $8k; all receive option grants under 2022 Plan.

## SEC filing metadata
- accession: 0001493152-23-000844
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/0001493152-23-000844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-000844
- JSON: https://secwatch.observer/filing/0001493152-23-000844.json
- Plain text: https://secwatch.observer/filing/0001493152-23-000844.txt

## Key facts
- Executive change
  James Sapirstein was appointed as Director at ZyVersa Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 5, 2023, the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company” or “ZyVersa”), appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as members of the board to fill the three vacancies created as a result of the business combination between ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”) with Larkspur Health Acquisition Corp. (“Larkspur”), which was consummated on December 12, 2022 (the “Business Combination”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/0001493152-23-000844-index.htm
- Executive change
  Gregory Freitag was appointed as Director at ZyVersa Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 5, 2023, the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company” or “ZyVersa”), appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as members of the board to fill the three vacancies created as a result of the business combination between ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”) with Larkspur Health Acquisition Corp. (“Larkspur”), which was consummated on December 12, 2022 (the “Business Combination”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/0001493152-23-000844-index.htm
- Executive change
  Katrin Rupalla was appointed as Director at ZyVersa Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 5, 2023, the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company” or “ZyVersa”), appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as members of the board to fill the three vacancies created as a result of the business combination between ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”) with Larkspur Health Acquisition Corp. (“Larkspur”), which was consummated on December 12, 2022 (the “Business Combination”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/0001493152-23-000844-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.